Compound · clinical trials

Cytoxan clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 75 trials in our Israel, Canada, Australia, Mexico, USA, Spain, China, France, Poland, Italy, South Korea, Germany, Belgium, Taiwan, UK, Brazil, Egypt, Turkey, Japan, Austria, Czechia, Denmark, Ireland, Singapore, Switzerland, Netherlands, Portugal, Sweden, Norway and India registers that name Cytoxan as an intervention. Synced 9 Nov 2026

75Current trials

37Recruiting now

30Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Cytoxan is named as an intervention in 75 current clinical trials in our Israel, Canada, Australia, Mexico, USA, Spain, China, France, Poland, Italy, South Korea, Germany, Belgium, Taiwan, UK, Brazil, Egypt, Turkey, Japan, Austria, Czechia, Denmark, Ireland, Singapore, Switzerland, Netherlands, Portugal, Sweden, Norway and India registers. 37 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (19). The most-studied condition is Acute Lymphoblastic Leukemia.

Patient leaflets for Cytoxan

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting3749%
Not yet open11%
Active, closed3749%

Trials by phase

Phase 33749%
Phase 22027%
Phase 168%
Phase 2/357%
Phase 1/257%
Not applicable11%
Phase 411%

Clinical trials of Cytoxan

75 trials

Study	Phase	Status	Lead sponsor	Registers
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) NCT03126916 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Israel
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy NCT03959085 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma NCT05304585 · ClinicalTrials.gov ↗ · Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss NCT05382338 · Childhood Medulloblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Israel
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab NCT05675410 · ClinicalTrials.gov ↗ · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer NCT05929768 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8	Phase 3	Recruiting	SWOG Cancer Research Network	Mexico, Israel
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis NCT06022939 · ClinicalTrials.gov ↗ · AL Amyloidosis	Phase 3	Recruiting	SWOG Cancer Research Network	Egypt
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer NCT06058377 · ClinicalTrials.gov ↗ · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Israel
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma NCT06091254 · Follicular Lymphoma (FL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma NCT06091865 · Diffuse Large B-cell Lymphoma (DLBCL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma NCT06172296 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) NCT06401330 · Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor	Phase 3	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma NCT06647953 · ClinicalTrials.gov ↗ · Pleuropulmonary Blastoma	Phase 3	Recruiting	Children's Oncology Group	Canada
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) NCT06717347 · Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	USA, China, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) NCT06983821 · ClinicalTrials.gov ↗ · Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)	Phase 3	Recruiting	Ottawa Hospital Research Institute	Canada
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) NCT07466316 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma	Phase 3	Recruiting	Children's Oncology Group	Canada
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) NCT07634471 · Follicular Lymphoma	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	USA, China, Spain, Italy, Poland, Turkey, South Korea, Taiwan, Australia, Israel
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT NCT04322318 · ClinicalTrials.gov ↗ · Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor	Phase 2	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT04920617 · Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma	Phase 2	Recruiting	ImmunoVaccine Technologies, Inc. (IMV Inc.)	USA, France, Spain, Poland, Canada, Australia
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT05633615 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma	Phase 2	Recruiting	SWOG Cancer Research Network	Mexico
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma NCT05800366 · ClinicalTrials.gov ↗ · Lymphoma, Lymphoma, Large B-Cell, Diffuse	Phase 2	Recruiting	Jennifer Crombie, MD	Israel
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT06124157 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL NCT06500273 · Large B-cell Lymphoma	Phase 2	Recruiting	Allogene Therapeutics	USA, Canada, South Korea, Australia, Israel
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors NCT06528691 · ClinicalTrials.gov ↗ · High Grade Glioma, CNS Tumor	Phase 2	Recruiting	St. Jude Children's Research Hospital	Brazil
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635 · Breast Neoplasms, Breast Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, South Korea, Taiwan
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) NCT06890884 · Lymphoma, Large B-Cell, Diffuse	Phase 2	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, Germany, Italy, Belgium, Poland, Japan, Israel, Egypt
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL NCT07493148 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Recruiting	Ou Bai, MD/PHD	China
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors NCT02813135 · ClinicalTrials.gov ↗ · Pediatric Cancer	Phase 1/2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France, Spain, Italy, Netherlands, Denmark
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers NCT05296564 · ClinicalTrials.gov ↗ · Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV	Phase 1/2	Recruiting	Hadassah Medical Organization	Israel
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer NCT05323201 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 1/2	Recruiting	The Affiliated Hospital of Xuzhou Medical University	China
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma NCT07622940 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease	Phase 1/2	Recruiting	Beijing Biotech	China
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma NCT05618925 · Non Hodgkin's Lymphoma Refractory/Relapsed	Phase 1	Recruiting	ImmunityBio, Inc	USA
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma NCT06153251 · Relapsed and/or Refractory Multiple Myeloma	Phase 1	Recruiting	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	USA, Germany, France, Spain
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease NCT06308978 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)	Phase 1	Recruiting	Fate Therapeutics	UK, USA, France, Sweden
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer NCT07641049 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer	Phase 1	Recruiting	Beijing Biotech	China
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH NCT05936086 · ClinicalTrials.gov ↗ · Hemophagocytic Syndrome	Not applicable	Recruiting	shifeng Lou	China
The CARDIOPROTECT Trial NCT07654426 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma	Phase 2	Not yet open	Beth Israel Deaconess Medical Center	Israel
A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis NCT05300932 · ClinicalTrials.gov ↗ · Systemic Sclerosis	Phase 4	Active, closed	Tongji Hospital	China
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer NCT00433511 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia NCT02003222 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT02048813 · ClinicalTrials.gov ↗ · Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia NCT02101853 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia, Israel
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma NCT02112916 · ClinicalTrials.gov ↗ · Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma NCT02166463 · ClinicalTrials.gov ↗ · Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma NCT02176967 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma NCT02306161 · ClinicalTrials.gov ↗ · Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer NCT02488967 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative	Phase 3	Active, closed	NRG Oncology	Norway, Canada, Israel, Egypt
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma NCT02567435 · ClinicalTrials.gov ↗ · Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia, Israel
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT03007147 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia	Phase 3	Active, closed	Children's Oncology Group	Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Canada, Mexico, Australia, Israel
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents NCT03020030 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Active, closed	Dana-Farber Cancer Institute	Canada
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) NCT03725059 · Breast Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Belgium, Poland, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel, Egypt
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia NCT03914625 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults NCT04530565 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma NCT04759586 · ClinicalTrials.gov ↗ · Primary Mediastinal Large B-Cell Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma NCT04994132 · ClinicalTrials.gov ↗ · Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Australia, Israel
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer NCT05113251 · Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome NCT05457556 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia	Phase 3	Active, closed	Children's Oncology Group	Canada, Australia
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation NCT06045806 · Multiple Myeloma	Phase 3	Active, closed	Celgene	UK, USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Norway, Canada, Japan, South Korea, Australia, Israel
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma NCT06097364 · Follicular Lymphoma (FL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Turkey, Brazil, Taiwan, Australia, Israel
Mature B-Cell Lymphoma And Leukemia Study III NCT01046825 · ClinicalTrials.gov ↗ · Mature B-Cell Lymphoma	Phase 2/3	Active, closed	St. Jude Children's Research Hospital	Singapore, Egypt
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma NCT03117751 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma	Phase 2/3	Active, closed	St. Jude Children's Research Hospital	Australia
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas NCT03984448 · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma NCT04799275 · ClinicalTrials.gov ↗ · Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Israel
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma NCT01856192 · ClinicalTrials.gov ↗ · Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia NCT02251548 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Leukemia	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma NCT02724579 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Active, closed	Children's Oncology Group	Canada, Australia, Israel
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia NCT02981628 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia	Phase 2	Active, closed	Children's Oncology Group	Israel
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma NCT03113500 · ClinicalTrials.gov ↗ · Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive	Phase 2	Active, closed	City of Hope Medical Center	Canada
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma NCT03269669 · ClinicalTrials.gov ↗ · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) NCT05406401 · ClinicalTrials.gov ↗ · Lymphoma, Large B-Cell, Diffuse (DLBCL)	Phase 2	Active, closed	Merck Sharp & Dohme LLC	Spain, Italy, Poland, Turkey, Canada, South Korea, Israel
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL NCT07480863 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL)	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I NCT02553460 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 1/2	Active, closed	St. Jude Children's Research Hospital	Canada
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma NCT02298348 · ClinicalTrials.gov ↗ · Neuroblastoma	Phase 1	Active, closed	New Approaches to Neuroblastoma Therapy Consortium	Canada
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma NCT06961786 · ClinicalTrials.gov ↗ · Metastatic Melanoma	Phase 1	Active, closed	TILT Biotherapeutics Ltd	Denmark

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Cytoxan

134 conditions

Acute Lymphoblastic Leukemia5B Acute Lymphoblastic Leukemia4Neuroblastoma4 Breast Cancer3 Diffuse Large B-Cell Lymphoma3Mixed Phenotype Acute Leukemia3Embryonal Rhabdomyosarcoma3Lymphoma, Large B-Cell, Diffuse2Diffuse Large B-cell Lymphoma (DLBCL)2 Follicular Lymphoma (FL)2 Multiple Myeloma2 Breast Neoplasms2

All 134 conditions

Condition (as registered)	Trials
Acute Lymphoblastic Leukemia	5
B Acute Lymphoblastic Leukemia	4
Neuroblastoma	4
Breast Cancer	3
Diffuse Large B-Cell Lymphoma	3
Mixed Phenotype Acute Leukemia	3
Embryonal Rhabdomyosarcoma	3
Lymphoma, Large B-Cell, Diffuse	2
Diffuse Large B-cell Lymphoma (DLBCL)	2
Follicular Lymphoma (FL)	2
Multiple Myeloma	2
Breast Neoplasms	2
Breast Adenocarcinoma	2
Recurrent B Acute Lymphoblastic Leukemia	2
Alveolar Rhabdomyosarcoma	2
Botryoid-Type Embryonal Rhabdomyosarcoma	2
Rhabdomyosarcoma	2
Ganglioneuroblastoma	2
Ganglioneuroblastoma, Nodular	2
B Lymphoblastic Lymphoma	2
Anatomic Stage II Breast Cancer AJCC v8	2
Chronic Lymphocytic Leukemia	2
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma	2
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	2
Lymphoma	2
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)	1
Idiopathic Inflammatory Myositis (IIM)	1
Systemic Sclerosis (SSc)	1
Systemic Lupus Erythematosus (SLE)	1
Relapsed Diffuse Large B-cell Lymphoma	1
Refractory Diffuse Large B-cell Lymphoma	1
HER2-positive Early Breast Cancer	1
Non Hodgkin's Lymphoma Refractory/Relapsed	1
Large B-cell Lymphoma	1
Follicular Lymphoma	1
Relapsed and/or Refractory Multiple Myeloma	1
Hepatocellular Carcinoma	1
Diffuse Large B-Cell Lymphoma (DLBCL)	1
Hemophagocytic Syndrome	1
Metastatic Castration-resistant Prostate Cancer	1
Advanced Prostate Adenocarcinoma	1
PSCA-positive Prostate Cancer	1
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer	1
Systemic Sclerosis	1
Marginal Zone Lymphoma(MZL)	1
Primary Plasma Cell Leukemia	1
Extramedullary Multiple Myeloma	1
Recurrent or Metastatic Esophageal Adenocarcinoma	1
Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease	1
T Acute Lymphoblastic Leukemia	1
Pediatric Cancer	1
Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
Metastatic Melanoma	1
Estrogen Receptor Negative	1
HER2/Neu Negative	1
Progesterone Receptor Negative	1
Acute Lymphoblastic Leukemia, Pediatric	1
Metastatic Embryonal Rhabdomyosarcoma	1
Childhood Medulloblastoma	1
Anaplastic Kidney Wilms Tumor	1
Recurrent Kidney Wilms Tumor	1
Stage II Kidney Wilms Tumor	1
Stage III Kidney Wilms Tumor	1
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1
Primary Mediastinal Large B-Cell Lymphoma	1
Fusion-Negative Alveolar Rhabdomyosarcoma	1
Spindle Cell/Sclerosing Rhabdomyosarcoma	1
Adult T-Cell Leukemia/Lymphoma	1
Anaplastic Large Cell Lymphoma, ALK-Negative	1
Anaplastic Large Cell Lymphoma, ALK-Positive	1
Angioimmunoblastic T-Cell Lymphoma	1
Metastatic Ewing Sarcoma	1
Metastatic Malignant Neoplasm in the Bone	1
Metastatic Malignant Neoplasm in the Bone Marrow	1
Metastatic Malignant Neoplasm in the Lung	1
Central Nervous System Leukemia	1
Localized Resectable Neuroblastoma	1
Localized Unresectable Neuroblastoma	1
Down Syndrome	1
Adult T Acute Lymphoblastic Leukemia	1
Ann Arbor Stage II Adult Lymphoblastic Lymphoma	1
Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	1
Ann Arbor Stage III Adult Lymphoblastic Lymphoma	1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	1
Medulloblastoma	1
Pleuropulmonary Blastoma	1
Ann Arbor Stage IIB Hodgkin Lymphoma	1
Ann Arbor Stage IIIB Hodgkin Lymphoma	1
Ann Arbor Stage IVA Hodgkin Lymphoma	1
Ann Arbor Stage IVB Hodgkin Lymphoma	1
Granulomatosis With Polyangiitis	1
Microscopic Polyangiitis (MPA)	1
Stage I Mixed Cell Type Kidney Wilms Tumor	1
Stage II Mixed Cell Type Kidney Wilms Tumor	1
Stage III Mixed Cell Type Kidney Wilms Tumor	1
Stage IV Mixed Cell Type Kidney Wilms Tumor	1
Acute Myeloid Leukemia	1
Myelodysplastic Syndrome	1
High Grade Glioma	1
CNS Tumor	1
Anatomic Stage I Breast Cancer AJCC v8	1
Anatomic Stage IIIA Breast Cancer AJCC v8	1
Anatomic Stage IIIB Breast Cancer AJCC v8	1
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Double-Expressor Lymphoma	1
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Grade 3b Follicular Lymphoma	1
Primary Mediastinal (Thymic) Large B-Cell Lymphoma	1
Recurrent Diffuse Large B-Cell Lymphoma	1
Grade 1 Follicular Lymphoma	1
Grade 2 Follicular Lymphoma	1
Grade 3a Follicular Lymphoma	1
Recurrent Follicular Lymphoma	1
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	1
Anemia	1
Small Lymphocytic Lymphoma	1
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma	1
Mature B-Cell Lymphoma	1
Acute Lymphoblastic Lymphoma	1
Recurrent B Lymphoblastic Lymphoma	1
Refractory B Acute Lymphoblastic Leukemia	1
Refractory B Lymphoblastic Lymphoma	1
Sarcoma, Synovial	1
Sarcoma,Soft Tissue	1
Melanoma Stage IV	1
Triple Negative Breast Cancer	1
Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma	1
Diffuse Large B-Cell Lymphoma Activated B-Cell Type	1
Leukemia	1
Anatomic Stage III Breast Cancer AJCC v8	1
HER2-Negative Breast Carcinoma	1
Hormone Receptor-Positive Breast Carcinoma	1
Cardiotoxicity	1
AL Amyloidosis	1

By country register

Register	Trials	Recruiting
Clinical trials in Israel	42	18
Clinical trials in Canada	38	16
Clinical trials in Australia	26	12
Clinical trials in Mexico	21	10
Clinical trials in USA	15	11
Clinical trials in Spain	13	8
Clinical trials in China	12	8
Clinical trials in France	11	7
Clinical trials in Poland	11	6
Clinical trials in Italy	11	6
Clinical trials in South Korea	10	6
Clinical trials in Germany	9	4
Clinical trials in Belgium	8	4
Clinical trials in Taiwan	8	5
Clinical trials in UK	7	4
Clinical trials in Brazil	7	4
Clinical trials in Egypt	6	3
Clinical trials in Turkey	6	4
Clinical trials in Japan	5	2
Clinical trials in Austria	5	2
Clinical trials in Czechia	4	2
Clinical trials in Denmark	4	2
Clinical trials in Ireland	3	2
Clinical trials in Singapore	3	2
Clinical trials in Switzerland	3	2
Clinical trials in Netherlands	3	2
Clinical trials in Portugal	2	1
Clinical trials in Sweden	2	1
Clinical trials in Norway	2	0
Clinical trials in India	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Cytoxan trials

How many clinical trials are testing Cytoxan?

75 current trials in our Israel, Canada, Australia, Mexico, USA, Spain, China, France, Poland, Italy, South Korea, Germany, Belgium, Taiwan, UK, Brazil, Egypt, Turkey, Japan, Austria, Czechia, Denmark, Ireland, Singapore, Switzerland, Netherlands, Portugal, Sweden, Norway and India registers name Cytoxan as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Cytoxan trials recruiting patients?

Yes. 37 of the 75 trials are recruiting: 18 with sites in Israel, 16 with sites in Canada, 12 with sites in Australia, 10 with sites in Mexico, 11 with sites in USA, 8 with sites in Spain, 8 with sites in China, 7 with sites in France, 6 with sites in Poland, 6 with sites in Italy, 6 with sites in South Korea, 4 with sites in Germany, 4 with sites in Belgium, 5 with sites in Taiwan, 4 with sites in UK, 4 with sites in Brazil, 3 with sites in Egypt, 4 with sites in Turkey, 2 with sites in Japan, 2 with sites in Austria, 2 with sites in Czechia, 2 with sites in Denmark, 2 with sites in Ireland, 2 with sites in Singapore, 2 with sites in Switzerland, 2 with sites in Netherlands, 1 with sites in Portugal and 1 with sites in Sweden. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Cytoxan clinical trials?

National Cancer Institute (NCI) (19), Children's Oncology Group (14), Merck Sharp & Dohme LLC (6) and St. Jude Children's Research Hospital (4), among 30 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Cytoxan clinical trials in Ireland?

Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cytoxan works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cytoxan works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cytoxan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.